The purpose of this study is to assess the clinical effectiveness by the clinical response at 6 weeks and the safety of vedolizumab intravenous in UC Korean participants.
This is a post-marketing, non-interventional study of participants with moderate to severe UC. The study will review medical records of participants who have initiated medical treatment with vedolizumab intravenous during the defined eligibility period under routine clinical practice to provide the real world data on the effectiveness and safety of vedolizumab intravenous. The study will enroll approximately 100 participants. All participants will be enrolled in one observational group: Vedolizumab Both retrospective and prospective data will be collected in the index period, with prospective data collected for treatment baseline visit and follow up visits. The multi-center trial will be conducted in Republic of Korea. The overall duration of study will be approximately 15 months.
Study Type
OBSERVATIONAL
Enrollment
105
Dankook University Hospital
Cheonan-si, Chungcheongnam-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Percentage of Participants With Clinical Response at Week 6 Based on Partial Mayo Score
Clinical response based on partial Mayo score was defined as a reduction of at least 3 points and a decrease of at least 30 percent (%) from the baseline Mayo score, with a decrease of at least 1 point on the rectal bleeding subscale, or an absolute rectal bleeding score of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. Partial Mayo score consisted of 3 sub-scores: stool frequency, most severe rectal bleeding of the day, and global assessment by physician, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score range of 0 to 9; where higher score indicated more severe disease.
Time frame: Week 6
Percentage of Participants With Adverse Events of Special Interests (AESIs) and Serious Adverse Events (SAEs)
Time frame: From the index date (date when vedolizumab treatment was initiated) until the end of treatment, lost to follow-up or death (up to 15 months)
Percentage of Participants With Pregnancy During the Study
Time frame: From the index date (date when vedolizumab treatment was initiated) until the end of treatment, lost to follow-up or death (up to 15 months)
Percentage of Participants With Clinical Response at Week 14 Based on Partial Mayo Score
Clinical response was defined as a reduction of at least 3 points and a decrease of at least 30% from the baseline mayo score, with a decrease of at least 1 point on the rectal bleeding subscale, or an absolute rectal bleeding score of 0 or 1. Mayo score was an instrument designed to measure disease activity of UC. Partial Mayo score consisted of 3 sub-scores: stool frequency, most severe rectal bleeding of the day, endoscopic findings and global assessment by physician, each graded from 0 to 3 with higher scores indicating more severe disease. These scores are summed to give a total score range of 0 to 9. Here, higher scores indicated more severe disease.
Time frame: Week 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Catholic University of Korea, St. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea
Inje University Haeundae Paik Hospita
Busan, South Korea
Kyungpook National University Hospital
Daegu, South Korea
Youngnam University Hospital
Daegu, South Korea
Goo Hospital
Daegu, South Korea
The Catholic University of Korea, Daejeon St. Mary's Hospital
Daejeon, South Korea
Kyung Hee University Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
...and 5 more locations
Percentage of Participants With Clinical Remission at Week 6 and Week 14 Based on Partial Mayo Score
Clinical remission was defined as a total mayo score of less than or equal to (\<=) 2 with no sub-score greater than (\>) 1. Mayo score was an instrument designed to measure disease activity of UC. Partial Mayo score consisted of 3 sub-scores: stool frequency, most severe rectal bleeding of the day, and global assessment by physician, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score range of 0 to 9; where higher score indicated more severe disease.
Time frame: Weeks 6 and 14
Percentage of Participants With Mucosal Healing at Weeks 6 and 14
Mucosal healing was defined as Mayo endoscopic sub-score of 0 or 1 compared to baseline. Mayo score was an instrument designed to measure disease activity of UC. Endoscopic findings was a sub-score of complete Mayo score, which ranges from 0 to 3 (0= Normal or inactive disease; 1= Mild disease; 2= Moderate disease; 3= Severe disease), with higher scores indicating more severe disease.
Time frame: Weeks 6 and 14